Sanyou Bio and KanryBio Form Strategic Partnership to Advance Biomarker Assay Kit Development
核心洞察
Sanyou Biopharmaceuticals (搜索) and Wenzhou KanryBio (搜索) announced a strategic collaboration on December 10, 2025, to co-develop key reagents and products for biomarker (搜索) assay kits.
The partnership combines Sanyou Bio's AI Super-Trillion-Level (搜索) intelligent molecular library with KanryBio (搜索)'s expertise in kit development and manufacturing to accelerate drug development processes.
The collaboration aims to create high-performance, domestically produced assay kits with superior cost-effectiveness, reducing dependence on imported products in precision medicine applications.
Sanyou Biopharmaceuticals (搜索) (Shanghai) Co., Ltd. and Wenzhou KanryBio Biotech Co., Ltd. (搜索) announced a strategic collaboration agreement on December 10, 2025, focusing on the joint development of key reagents and products for biomarker (搜索) assay kits. The partnership aims to provide global biopharmaceutical R&D clients with more efficient, precise, and reliable total solutions for biomarker detection, thereby accelerating drug development and companion diagnostic processes.
Strategic Technology Integration
The collaboration leverages complementary strengths from both organizations. Sanyou Bio will contribute its globally leading AI Super-Trillion-Level (搜索) (AI-STAL) intelligent molecular library and integrated drug discovery platform to drive innovative discovery and optimization of high-performance antibodies (搜索) and other key reagents targeting specific biomarkers. KanryBio (搜索) brings extensive experience in high-end analytical instruments, high-value consumables, and kit development, along with international-standard production and quality control systems to ensure scalable manufacturing, performance validation, and stable supply of co-developed products.
Core Value Creation
The partnership targets value creation across three key dimensions. First, the joint development will shorten the timeline from discovery to productization of high-performance biomarker (搜索) detection reagents, helping pharmaceutical companies expedite patient stratification, efficacy evaluation, and companion diagnostic development. Second, combining Sanyou Bio's source innovation with KanryBio (搜索)'s engineering and cost-control capabilities will create high-end, domestically produced assay kits with superior performance, stable supply, and higher cost-effectiveness, reducing dependence on imported products in certain fields. Third, by pooling market resources, both companies will jointly promote co-developed kit products and solutions, offering superior options to biopharmaceutical companies, CROs, and diagnostic firms worldwide.
Leadership Perspectives
Dr. Linglong Zou, Chairman and CEO of KanryBio (搜索), stated: "We are thrilled to partner with Sanyou Bio. Their exceptional capabilities in ultra-large-capacity molecular libraries and intelligent screening are impressive. This collaboration provides KanryBio with a powerful innovation engine for the 'upstream' of kit product development. We believe the deep integration of 'discovery + translation' will enable us to respond rapidly to market needs and develop high-quality biomarker (搜索) detection products that address real customer pain points, jointly advancing industry technology."
Dr. Guojun Lang, Founder and CEO of Sanyou Bio, commented: "The collaboration with KanryBio (搜索) is a significant extension of Sanyou Bio's mission—'to make innovative biologics accessible to all'—into the field of precision diagnostics. KanryBio's proven 'hard strength' in systematic kit development and production is widely recognized. This strategic synergy is a key step in connecting our molecular discovery capabilities with an industrial partner's engineering platform."
Company Capabilities
KanryBio (搜索) leverages the scientific and technological strengths of the Wenzhou Institute of the Chinese Academy of Sciences, specializing in R&D, production, and sales of high-end analytical instruments, high-value consumables, and reagents. The company's pilot production workshop has obtained ISO9001 quality management system certification and focuses on developing electrochemiluminescence analysis platforms, cell sorting platforms, and intelligent laboratory automation platforms.
Sanyou Bio operates as a high-tech biopharmaceutical enterprise driven by its super-trillion molecule library and artificial intelligence technology. The company has established collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, with over 10 advancing to IND approval and clinical development stages. The company has filed over 130 invention patents, with more than 30 granted, and operates over 20,000 square meters of R&D and GMP facilities.